Oyster Point Pharma, Inc.

2022 Q4 Form 10-Q Financial Statement

#000172072522000080 Filed on November 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $68.80M $184.2M
YoY Change -62.64% -14.06%
Cash & Equivalents $68.80M $184.2M
Short-Term Investments
Other Short-Term Assets $8.764M $3.020M
YoY Change 190.2% 235.56%
Inventory $6.959M
Prepaid Expenses
Receivables $13.18M
Other Receivables $0.00
Total Short-Term Assets $97.71M $189.7M
YoY Change -48.49% -11.85%
LONG-TERM ASSETS
Property, Plant & Equipment $2.438M $1.976M
YoY Change 23.38% 324.03%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $886.0K
YoY Change
Other Assets $5.692M $2.635M
YoY Change 116.02% 2535.0%
Total Long-Term Assets $11.49M $5.323M
YoY Change 115.93% 308.21%
TOTAL ASSETS
Total Short-Term Assets $97.71M $189.7M
Total Long-Term Assets $11.49M $5.323M
Total Assets $109.2M $195.0M
YoY Change -44.0% -9.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.145M $3.506M
YoY Change 18.23% 53.03%
Accrued Expenses $24.36M $11.17M
YoY Change 118.01% 65.61%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $17.00K $17.00K
YoY Change 0.0%
Total Short-Term Liabilities $29.20M $15.16M
YoY Change 92.58% 60.48%
LONG-TERM LIABILITIES
Long-Term Debt $92.24M $41.93M
YoY Change 120.0%
Other Long-Term Liabilities $8.177M $238.0K
YoY Change 3335.71% -40.5%
Total Long-Term Liabilities $8.177M $42.34M
YoY Change -80.69% 10484.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $29.20M $15.16M
Total Long-Term Liabilities $8.177M $42.34M
Total Liabilities $131.4M $57.50M
YoY Change 128.54% 485.33%
SHAREHOLDERS EQUITY
Retained Earnings -$390.0M -$213.3M
YoY Change 82.84% 60.98%
Common Stock $27.00K $26.00K
YoY Change 3.85% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$22.20M $137.5M
YoY Change
Total Liabilities & Shareholders Equity $109.2M $195.0M
YoY Change -44.0% -9.92%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001720725
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39112
dei Entity Registrant Name
EntityRegistrantName
OYSTER POINT PHARMA, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-1030955
dei Entity Address Address Line1
EntityAddressAddressLine1
202 Carnegie Center, Suite 106
dei Entity Address City Or Town
EntityAddressCityOrTown
Princeton
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
08540
dei City Area Code
CityAreaCode
609
dei Local Phone Number
LocalPhoneNumber
382-9032
dei Security12b Title
Security12bTitle
Common stock, par value $0.001
dei Trading Symbol
TradingSymbol
OYST
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26844292 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68800000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
193372000 usd
CY2022Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
0 usd
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
61000 usd
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
13184000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6656000 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
6959000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
6086000 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8764000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9075000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
97707000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
215250000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2438000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2497000 usd
CY2022Q3 us-gaap Long Term Investments
LongTermInvestments
886000 usd
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
886000 usd
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5692000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1082000 usd
CY2022Q3 oyst Lease Right Of Use Asset
LeaseRightOfUseAsset
2478000 usd
CY2021Q4 oyst Lease Right Of Use Asset
LeaseRightOfUseAsset
2902000 usd
CY2022Q3 us-gaap Assets
Assets
109201000 usd
CY2021Q4 us-gaap Assets
Assets
222617000 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4145000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6496000 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24360000 usd
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
8177000 usd
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2345000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21511000 usd
CY2022Q3 oyst Lease Liability Current
LeaseLiabilityCurrent
692000 usd
CY2021Q4 oyst Lease Liability Current
LeaseLiabilityCurrent
795000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
29197000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
28802000 usd
CY2022Q3 oyst Lease Liability Noncurrent
LeaseLiabilityNoncurrent
1811000 usd
CY2021Q4 oyst Lease Liability Noncurrent
LeaseLiabilityNoncurrent
2118000 usd
CY2022Q3 us-gaap Long Term Debt
LongTermDebt
92218000 usd
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
89815000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
131403000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
123080000 usd
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
27000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
27000 usd
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26831485 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26831485 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26579585 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26579585 shares
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
1348000 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
367762000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
354920000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-389991000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-255410000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-22202000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
99537000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
109201000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
222617000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5591000 usd
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12988000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
CY2022Q3 us-gaap Revenues
Revenues
5591000 usd
CY2021Q3 us-gaap Revenues
Revenues
17943000 usd
us-gaap Revenues
Revenues
12988000 usd
us-gaap Revenues
Revenues
17943000 usd
CY2021Q3 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
us-gaap Cost Of Revenue
CostOfRevenue
2994000 usd
us-gaap Cost Of Revenue
CostOfRevenue
0 usd
CY2022Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
22094000 usd
CY2021Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
18170000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
77169000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
28947000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12149000 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10327000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
39079000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27938000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3913000 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6214000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13258000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18772000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
38156000 usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-902000 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
34711000 usd
us-gaap Operating Expenses
OperatingExpenses
129506000 usd
us-gaap Operating Expenses
OperatingExpenses
75657000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-33913000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-16768000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-119512000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-57714000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
3495000 usd
CY2021Q3 us-gaap Interest Expense
InterestExpense
1124000 usd
us-gaap Interest Expense
InterestExpense
9717000 usd
us-gaap Interest Expense
InterestExpense
1124000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
661000 usd
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
222000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5352000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
243000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2834000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-15069000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-881000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-36747000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36747000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-17670000 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17670000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-134581000 usd
us-gaap Net Income Loss
NetIncomeLoss
-134581000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-58595000 usd
us-gaap Net Income Loss
NetIncomeLoss
-58595000 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.37
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.37
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.25
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26830756 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26830756 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26037975 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26037975 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26736177 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26736177 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25984412 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25984412 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
99537000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-47892000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
76000 usd
CY2022Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
87000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4359000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
55993000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-49942000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
541000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4183000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
10775000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-36747000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3770000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-22202000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
186659000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-18909000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
218000 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2680000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
170648000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-22016000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
104000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3048000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
151784000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
137512000 usd
us-gaap Net Income Loss
NetIncomeLoss
-134581000 usd
us-gaap Net Income Loss
NetIncomeLoss
-58595000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
12312000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
8843000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
261000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
91000 usd
oyst Amortization And Accretion Of Long Term Debt Related Costs
AmortizationAndAccretionOfLongTermDebtRelatedCosts
3085000 usd
oyst Amortization And Accretion Of Long Term Debt Related Costs
AmortizationAndAccretionOfLongTermDebtRelatedCosts
508000 usd
oyst Leases Right Of Use Asset Amortization Expense
LeasesRightOfUseAssetAmortizationExpense
709000 usd
oyst Leases Right Of Use Asset Amortization Expense
LeasesRightOfUseAssetAmortizationExpense
371000 usd
us-gaap Inventory Write Down
InventoryWriteDown
-73000 usd
us-gaap Inventory Write Down
InventoryWriteDown
0 usd
oyst Revenue From Related Party Non Cash Consideration License Revenue
RevenueFromRelatedPartyNonCashConsiderationLicenseRevenue
0 usd
oyst Revenue From Related Party Non Cash Consideration License Revenue
RevenueFromRelatedPartyNonCashConsiderationLicenseRevenue
443000 usd
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
-5806000 usd
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
212000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6528000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5600000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-311000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-395000 usd
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
0 usd
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
2500000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
102000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
118000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2352000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1215000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-669000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-357000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2889000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2921000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
26000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-124506000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-47881000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
203000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1250000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-203000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1250000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
30000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
40151000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
429000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
26000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
14000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
87000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
542000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
0 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
76000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
605000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
76000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
40712000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-124633000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8419000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
193433000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
192646000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
68800000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
184227000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68800000 usd
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
184166000 usd
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
0 usd
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
61000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
68800000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
184227000 usd
us-gaap Interest Paid Net
InterestPaidNet
6632000 usd
us-gaap Interest Paid Net
InterestPaidNet
617000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
285000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
344000 usd
us-gaap Net Income Loss
NetIncomeLoss
-134600000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-390000000.0 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68800000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13000000 usd
CY2021Q3 oyst Line Of Credit Facility Recurring Revenue Contingency Requirement For Funding
LineOfCreditFacilityRecurringRevenueContingencyRequirementForFunding
40000000 usd
oyst Number Of Large Wholesale Drug Distributors
NumberOfLargeWholesaleDrugDistributors
4 distributor
us-gaap Use Of Estimates
UseOfEstimates
<div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities, disclosure of contingent assets and liabilities and the reported amounts of revenue and expenses in the financial statements and accompanying notes as of the date of the financial statements. On an ongoing basis, management evaluates its estimates, including those related to the valuation of stock-based awards, revenue and gross-to-net deductions, inventory, income taxes, net embedded derivative liability bifurcated from the Company's long-term credit agreement and certain research and development accruals. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates, and such differences could be material to the Company’s financial position and results of operations.</span></div>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
Reclassification<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The condensed statement of operations and comprehensive loss for the three and nine months ended September 30, 2021 has been conformed to separately present sales and marketing expenses which were previously reported in selling, general and administrative expenses</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</span> Certain prior year amounts have been reclassified for comparative purposes.
CY2022Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1144000 usd
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2524000 usd
CY2022Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
5500000 usd
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
3053000 usd
CY2022Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
315000 usd
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
509000 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
6959000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
6086000 usd
CY2022Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
4800000 usd
oyst Embedded Derivative Increase For Recognition Of Embedded Derivative Liability
EmbeddedDerivativeIncreaseForRecognitionOfEmbeddedDerivativeLiability
0 usd
oyst Embedded Derivative Increase For Recognition Of Embedded Derivative Liability
EmbeddedDerivativeIncreaseForRecognitionOfEmbeddedDerivativeLiability
450000 usd
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2750000 usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2734000 usd
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
312000 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
237000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2438000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2497000 usd
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3981000 usd
CY2022Q3 oyst Accrued Liabilities Accrued Gtn Deductions
AccruedLiabilitiesAccruedGTNDeductions
7762000 usd
CY2021Q4 oyst Accrued Liabilities Accrued Gtn Deductions
AccruedLiabilitiesAccruedGTNDeductions
4837000 usd
CY2022Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
10876000 usd
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
9153000 usd
CY2022Q3 oyst Accrued Inventory Current
AccruedInventoryCurrent
70000 usd
CY2021Q4 oyst Accrued Inventory Current
AccruedInventoryCurrent
594000 usd
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5451000 usd
CY2022Q3 oyst Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
1085000 usd
CY2021Q4 oyst Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
1156000 usd
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6603556 shares
CY2022Q3 oyst Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Performance Based Requirements Weighted Average Stock Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPerformanceBasedRequirementsWeightedAverageStockPrice
6.00
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
586000 usd
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
320000 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24360000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21511000 usd
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
oyst Common Stock Number Of Votes Per Share
CommonStockNumberOfVotesPerShare
1 vote
CY2022Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7680634 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4284072 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.54
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
28874000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1458967 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
14.45
oyst Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateIntrinsicValue
0 usd
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
69930 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.09
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
995000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
581966 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
17.44
oyst Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue
23000 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5091143 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.53
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M18D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3122000 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2562866 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.55
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y9M18D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3023000 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5091143 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
13.53
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y9M18D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
3122000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.32
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
25100000 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
179149 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
17.52
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P2Y4M24D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
3271000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
918357 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.43
oyst Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGrantsInPeriod
6822000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
60480 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
17.86
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
451000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
49598 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
14.37
oyst Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeituresInPeriod
251000 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
987428 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
8.27
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P2Y1M6D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
5549000 usd
CY2022Q3 oyst Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest
987428 shares
CY2022Q3 oyst Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue
8.27
oyst Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm
P2Y1M6D
CY2022Q3 oyst Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested And Expected To Vest
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest
5549000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3770000 usd
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3115000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12312000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8843000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-36747000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-17670000 usd
us-gaap Net Income Loss
NetIncomeLoss
-134581000 usd
us-gaap Net Income Loss
NetIncomeLoss
-58595000 usd
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26830756 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26830756 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26037975 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26037975 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26736177 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26736177 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25984412 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25984412 shares
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.37
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.37
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.25
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6822402 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4881553 shares
CY2022Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
95000000 usd
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
95000000 usd
CY2022Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
2782000 usd
CY2021Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
5185000 usd
CY2022Q3 us-gaap Long Term Debt
LongTermDebt
92218000 usd
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
89815000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
3500000 usd
us-gaap Interest Expense
InterestExpense
9700000 usd
CY2022Q3 us-gaap Lessee Finance Lease Remaining Lease Term
LesseeFinanceLeaseRemainingLeaseTerm
P3Y9M18D
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2444000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2884000 usd
CY2022Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
34000 usd
CY2021Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
18000 usd
CY2022Q3 oyst Lease Right Of Use Asset
LeaseRightOfUseAsset
2478000 usd
CY2021Q4 oyst Lease Right Of Use Asset
LeaseRightOfUseAsset
2902000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
675000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
779000 usd
CY2022Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
17000 usd
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
16000 usd
CY2022Q3 oyst Lease Liability Current
LeaseLiabilityCurrent
692000 usd
CY2021Q4 oyst Lease Liability Current
LeaseLiabilityCurrent
795000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1791000 usd
CY2022Q3 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
18000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
792000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2114000 usd
CY2022Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
20000 usd
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
4000 usd
CY2022Q3 oyst Lease Liability Noncurrent
LeaseLiabilityNoncurrent
1811000 usd
CY2021Q4 oyst Lease Liability Noncurrent
LeaseLiabilityNoncurrent
2118000 usd
CY2022Q3 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
4000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
194000 usd
CY2022Q3 oyst Lease Liability Payments Remainder Of Fiscal Year
LeaseLiabilityPaymentsRemainderOfFiscalYear
198000 usd
CY2022Q3 oyst Lease Liability Payments Due Next Twelve Months
LeaseLiabilityPaymentsDueNextTwelveMonths
810000 usd
CY2022Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
16000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
646000 usd
CY2022Q3 oyst Lease Liability Payments Due Year Two
LeaseLiabilityPaymentsDueYearTwo
662000 usd
CY2022Q3 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
0 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
562000 usd
CY2022Q3 oyst Lease Liability Payments Due Year Three
LeaseLiabilityPaymentsDueYearThree
562000 usd
CY2022Q3 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
0 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
525000 usd
CY2022Q3 oyst Lease Liability Payments Due Year Four
LeaseLiabilityPaymentsDueYearFour
525000 usd
CY2022Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
38000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2719000 usd
CY2022Q3 oyst Lease Liability Payment Due
LeaseLiabilityPaymentDue
2757000 usd
CY2022Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
1000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
253000 usd
CY2022Q3 oyst Lease Liability Undiscounted Excess Amount
LeaseLiabilityUndiscountedExcessAmount
254000 usd
CY2022Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
37000 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2466000 usd
CY2022Q3 oyst Lease Liability
LeaseLiability
2503000 usd
CY2022Q3 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
1700000 usd
CY2022Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
17000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
675000 usd
CY2022Q3 oyst Lease Liability Current
LeaseLiabilityCurrent
692000 usd
CY2022Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
20000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1791000 usd
CY2022Q3 oyst Lease Liability Noncurrent
LeaseLiabilityNoncurrent
1811000 usd
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000 usd
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
800000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
400000 usd
CY2022Q3 us-gaap Purchase Obligation
PurchaseObligation
5400000 usd
CY2022Q3 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
3700000 usd
CY2022Q3 oyst Purchase Obligation To Be Paid After Year One
PurchaseObligationToBePaidAfterYearOne
0 usd
us-gaap Unrecorded Unconditional Purchase Obligation Purchases
UnrecordedUnconditionalPurchaseObligationPurchases
8100000 usd
us-gaap Unrecorded Unconditional Purchase Obligation Purchases
UnrecordedUnconditionalPurchaseObligationPurchases
2300000 usd
CY2021 oyst Supply Commitment Initial Term
SupplyCommitmentInitialTerm
P3Y
CY2021 oyst Supply Commitment Minimum Capacity Reservation Fee
SupplyCommitmentMinimumCapacityReservationFee
2500000 usd

Files In Submission

Name View Source Status
0001720725-22-000080-index-headers.html Edgar Link pending
0001720725-22-000080-index.html Edgar Link pending
0001720725-22-000080.txt Edgar Link pending
0001720725-22-000080-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
oyst-20220930.htm Edgar Link pending
oyst-20220930.xsd Edgar Link pending
q32022-exhibit311xnau.htm Edgar Link pending
q32022-exhibit312xlochner.htm Edgar Link pending
q32022-exhibit321xnau.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
oyst-20220930_cal.xml Edgar Link unprocessable
oyst-20220930_def.xml Edgar Link unprocessable
oyst-20220930_lab.xml Edgar Link unprocessable
oyst-20220930_pre.xml Edgar Link unprocessable
oyst-20220930_htm.xml Edgar Link completed
q32022-exhibit322xlochner.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending